GeNeuro Reports 2019 Full-Year Results and Provides Corporate Update
Geneva, Switzerland, April 7, 2020 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, today reported its full-year results for the year ended December 31, 2019 and provided a corporate update https://geneuro.ch/data/news/GeNeuro-PR-FYR2019results.pdf